Elke Hunsche

Elke Hunsche,1 Viatcheslav G Rakov,1 Jennifer Coppola,2 Sanjay K Agarwal31Formerly at Sumitomo Pharma Switzerland GmbH, Basel, Switzerland; 2Formerly at Sumitomo Pharma America Inc., Cambridge, MA, USA; 3Department of OBGYN & Reproductive S…

Purpose: To characterize the experiences of individuals taking hormonal therapies to manage their symptoms of endometriosis (EM) or uterine fibroids (UF). Patients and Methods: This prospective, 16-week observational study enrolled US parti…

PURPOSE: To characterize the experiences of individuals taking hormonal therapies to manage their symptoms of endometriosis (EM) or uterine fibroids (UF). PATIENTS AND METHODS: This prospective, 16-week observational study enrolled US part…

BACKGROUND: Endometriosis symptoms have multifaceted manifestations, and there are few approved nonsurgical treatment options. Gonadotropin-releasing hormone (GnRH) agonists/antagonists for endometriosis vary on efficacy, safety profile, an…

BACKGROUND: Limited evidence is available regarding preferences of women with uterine fibroids (UF) and treating healthcare providers (HCPs) regarding treatment attributes; this evidence could contribute to patient-centered shared decision-…

OBJECTIVE: To evaluate the effect of relugolix combination therapy (relugolix CT; 40 mg relugolix, 1 mg estradiol, and 0.5 mg norethisterone acetate) for up to 2 years in the SPIRIT long-term extension study on functioning and health-relate…

PURPOSE: To characterize the burden of uterine fibroids (UF) in individuals experiencing heavy menstrual bleeding (HMB) and moderate-to-severe UF-associated pain in terms of symptoms experienced, impact on work and activities, and pain medi…

OBJECTIVE: This interview study sought to capture patients' experiences and perceptions of endometriosis symptoms and their impacts on daily life, as described by women in their own words. Using open-ended questions and a concept-elicitatio…